Free Trial
NASDAQ:ADGM

Adagio Medical Q3 2025 Earnings Report

Adagio Medical logo
$0.14 0.00 (-2.20%)
Closing price 04:00 PM Eastern
Extended Trading
$0.14 +0.00 (+2.17%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adagio Medical EPS Results

Actual EPS
-$0.66
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Adagio Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adagio Medical Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Adagio Medical's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Adagio Medical Earnings Headlines

Adagio Medical Converts Notes to Equity Amid Review
Adagio Medical (NASDAQ:ADGM) & Femasys (NASDAQ:FEMY) Financial Review
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Adagio Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adagio Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagio Medical and other key companies, straight to your email.

About Adagio Medical

Adagio Medical (NASDAQ:ADGM), Inc. is a medical-device company focused on developing catheter-based technologies for the treatment of cardiac arrhythmias, including atrial fibrillation. The company’s work is centered on cardiac ablation, a procedure that uses energy to create targeted lesions in heart tissue responsible for abnormal electrical signals.

Its lead technology is the iCLAS system, an integrated cardiac liquid ablation platform designed to support cardiac ablation procedures using ultra-low-temperature cryoablation and pulsed-field ablation capabilities. The system is intended to help physicians treat arrhythmias through catheter-based procedures, with potential applications that include persistent atrial fibrillation and other complex rhythm disorders. Product availability and regulatory authorization may vary by geography and indication.

Adagio Medical was founded in 2011 and is based in Laguna Hills, California. The company has focused primarily on research, clinical development and regulatory advancement of its ablation platform, serving the global electrophysiology and cardiovascular-care markets. Its leadership has included founder and Chief Executive Officer Olav Bergheim.

View Adagio Medical Profile